We are starting to get some meaningful data this week and while I suspect it will have some broader upside today, I will be curious to see if the sector.

Already a year has passed since Sarepta’s first drug Exondys51 was granted FDA approval on 09/19/2016. The landmark decision by Janet Woodcock, despite the review team’s opposition, gave hope to.

I have been looking around for real meaningful news this morning and there does not seem to be anything compelling. As such, I expect a trend day with the sector.

*** David Sobek is a disciplined value investor.  Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.

It still looks to me that the sector is acting less like a sector and more like an aggregation of individual stocks. That is always true (it is not a.

The sector in general appears to be treading water at these levels but that seems to belie the larger moves under the surface. I think keeping these levels and having.